Literature DB >> 18440922

Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings.

Jeffrey S Barrett1, Michael J Fossler, K David Cadieu, Marc R Gastonguay.   

Abstract

Pharmacometrics has evolved beyond quantitative analysis methods used to facilitate decision making in drug development, although the application of the discipline in this arena continues to represent the primary emphasis of scientists calling themselves pharmacometricians. While related fields populate and interface with pharmacometrics, there is a natural synergy with clinical pharmacology due to common areas of research and the decision-making expectation with respect to evolving conventional and translational research paradigms. Innovative and adaptable training programs and resources are essential in this regard as both disciplines promise to be key elements of the clinical research workplace of the future. The demand for scientists with pharmacometrics skills has risen substantially. Likewise, the salary garnered by those with these skills appears to be surpassing their counterparts without such backgrounds. Given the paucity of existing training programs, available training materials, and academic champions, a virtual faculty and online curriculum would allow students to matriculate into one of several programs associated with their advisor but take instruction from faculty at multiple institutions, including instructors in both industrial and regulatory settings. Flexibility in both the curriculum and the governance of the degree would provide the greatest hope of addressing the short supply of trained pharmacometricians.

Mesh:

Year:  2008        PMID: 18440922     DOI: 10.1177/0091270008315318

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  24 in total

1.  Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R.

Authors:  Michael N Neely; Michael G van Guilder; Walter M Yamada; Alan Schumitzky; Roger W Jelliffe
Journal:  Ther Drug Monit       Date:  2012-08       Impact factor: 3.681

2.  Concepts and challenges in quantitative pharmacology and model-based drug development.

Authors:  Liping Zhang; Marc Pfister; Bernd Meibohm
Journal:  AAPS J       Date:  2008-11-12       Impact factor: 4.009

3.  A population pharmacokinetic and pharmacodynamic study of a peripheral κ-opioid receptor agonist CR665 and oxycodone.

Authors:  Anne E Olesen; Kim Kristensen; Camilla Staahl; Sherron Kell; Gilbert Y Wong; Lars Arendt-Nielsen; Asbjørn M Drewes
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

Review 4.  Dosage individualization in children: integration of pharmacometrics in clinical practice.

Authors:  Wei Zhao; Stéphanie Leroux; Evelyne Jacqz-Aigrain
Journal:  World J Pediatr       Date:  2014-08-15       Impact factor: 2.764

5.  Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation.

Authors:  S F Marshall; R Burghaus; V Cosson; S Y A Cheung; M Chenel; O DellaPasqua; N Frey; B Hamrén; L Harnisch; F Ivanow; T Kerbusch; J Lippert; P A Milligan; S Rohou; A Staab; J L Steimer; C Tornøe; S A G Visser
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-03-14

6.  Modeling NSCLC progression: recent advances and opportunities available.

Authors:  Ahmed Abbas Suleiman; Lucia Nogova; Uwe Fuhr
Journal:  AAPS J       Date:  2013-02-13       Impact factor: 4.009

Review 7.  Multi-scale Modeling in Clinical Oncology: Opportunities and Barriers to Success.

Authors:  Thomas E Yankeelov; Gary An; Oliver Saut; E Georg Luebeck; Aleksander S Popel; Benjamin Ribba; Paolo Vicini; Xiaobo Zhou; Jared A Weis; Kaiming Ye; Guy M Genin
Journal:  Ann Biomed Eng       Date:  2016-07-06       Impact factor: 3.934

8.  White paper: landscape on technical and conceptual requirements and competence framework in drug/disease modeling and simulation.

Authors:  G Vlasakakis; E Comets; A Keunecke; I Gueorguieva; P Magni; N Terranova; O Della Pasqua; E C de Lange; C Kloft
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-05-01

9.  Comparisons of Analysis Methods for Proof-of-Concept Trials.

Authors:  K E Karlsson; C Vong; M Bergstrand; E N Jonsson; M O Karlsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-01-16

10.  CPT: Pharmacometrics and Systems Pharmacology.

Authors:  Piet H van der Graaf
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.